Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LGVN 
Longeveron LLC (LGVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: LGVN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.86
1 Year Target Price $6.86
| 0 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -91.37% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.43M USD | Price to earnings Ratio 3.31 | 1Y Target Price 6.86 |
Price to earnings Ratio 3.31 | 1Y Target Price 6.86 | ||
Volume (30-day avg) 3 | Beta 0.15 | 52 Weeks Range 0.63 - 2.48 | Updated Date 10/16/2025 |
52 Weeks Range 0.63 - 2.48 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1707.91% |
Management Effectiveness
Return on Assets (TTM) -67.48% | Return on Equity (TTM) -134.52% |
Valuation
Trailing PE 3.31 | Forward PE - | Enterprise Value 6921822 | Price to Sales(TTM) 8.41 |
Enterprise Value 6921822 | Price to Sales(TTM) 8.41 | ||
Enterprise Value to Revenue 3.34 | Enterprise Value to EBITDA -49.61 | Shares Outstanding 19576924 | Shares Floating 11351146 |
Shares Outstanding 19576924 | Shares Floating 11351146 | ||
Percent Insiders 15.09 | Percent Institutions 6.87 |
Upturn AI SWOT
Longeveron LLC
Company Overview
History and Background
Longeveron Inc. was founded in 2014 and is a clinical stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. They focus on using allogeneic, human Mesenchymal Stem Cells (MSCs) to address unmet medical needs.
Core Business Areas
- Regenerative Medicine: Developing and commercializing cell-based therapies for aging-related diseases and other life-threatening conditions.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their MSC-based therapies.
Leadership and Structure
The leadership team includes key executives focused on research and development, clinical trials, and business operations. Details on the full organizational structure are available in public filings.
Top Products and Market Share
Key Offerings
- Lomecel-B: Longeveron's lead investigational product, Lomecel-B, is being developed for aging-related conditions, including Alzheimeru2019s disease and Hypoplastic Left Heart Syndrome (HLHS). As Lomecel-B is not approved for any indication, there is no revenue generated. Competitors include companies developing other MSC-based therapies and treatments for Alzheimer's and HLHS.
Market Dynamics
Industry Overview
The regenerative medicine industry is experiencing significant growth, driven by advancements in cell therapy and increasing demand for effective treatments for chronic diseases.
Positioning
Longeveron is positioned as a clinical-stage company focused on developing MSC-based therapies. Their competitive advantage lies in their proprietary MSC technology and clinical trial expertise.
Total Addressable Market (TAM)
The TAM for regenerative medicine is projected to reach billions of dollars in the coming years. Longeveron's positioning is focused on capturing a share of this market by developing treatments for specific indications like Alzheimer's and HLHS.
Upturn SWOT Analysis
Strengths
- Proprietary MSC technology
- Experienced management team
- Advanced clinical development pipeline
- Focus on unmet medical needs
Weaknesses
- Reliance on successful clinical trial outcomes
- High cash burn rate
- Limited commercialization experience
- Dependence on future financing
Opportunities
- Positive clinical trial results
- Regulatory approvals
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Competition from other regenerative medicine companies
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- MESO
- ATHX
- CRIS
Competitive Landscape
Longeveron faces competition from other regenerative medicine companies, including those with more advanced clinical programs and greater financial resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increasing R&D spending and clinical trial activity.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary based on the likelihood of these events.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Lomecel-B in Alzheimer's disease and HLHS.
Summary
Longeveron is a high-risk, high-reward clinical-stage biotechnology company. Its strengths lie in its proprietary MSC technology and clinical programs, while weaknesses include its high cash burn and dependence on clinical trial success. Positive clinical trial outcomes and regulatory approvals would significantly enhance its prospects, while failure in trials would jeopardize its future. They have significant competition in the overall regenerative medicine market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Longeveron LLC
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2021-02-12 | Interim CEO & Director Mr. Than Powell | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | Website https://longeveron.com |
Full time employees 25 | Website https://longeveron.com | ||
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.